المؤلفون: NRG Oncology

المصدر: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04739800Test

المؤلفون: National Cancer Institute (NCI)

المصدر: Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04575935Test

Other URLs: http://www.mdanderson.orgTest

المصدر: A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04092270Test

المؤلفون: National Cancer Institute (NCI)

المساهمون: Kathryn Pennington, Assistant Professor

المصدر: The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors - A Randomized Controlled Trial

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03641287Test

المؤلفون: National Cancer Institute (NCI)

المصدر: A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02923739Test

Other URLs: http://www.mdanderson.orgTest

المصدر: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02834013Test

المؤلفون: National Cancer Institute (NCI)

المصدر: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00108745Test

المؤلفون: NRG Oncology

المصدر: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00262847Test

المؤلفون: NRG Oncology

المصدر: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00565851Test

المؤلفون: National Cancer Institute (NCI)

المصدر: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00719303Test